A Targetable EGFR-Dependent Tumor-Initiating Program in Breast CancerPaul Savage, Jiannis Ragoussis, Marie‐Christine Guiot et al.|Cell Reports|2017Cited by 78
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasMatthew Dankner, April A. N. Rose, Mathieu Lajoie et al.|Clinical Cancer Research|2018Cited by 76
STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancerStephanie Totten, Josie Ursini‐Siegel, Young Kyuen Im et al.|Nature Communications|2021Cited by 61
Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumorsPaul Savage, Morag Park, Alain Pacis et al.|Communications Biology|2020Cited by 56
DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapyCynthia Bernier, Anne Roulston, Ahmed Soliman et al.|Anti-Cancer Drugs|2018Cited by 22